UCB's Global Corporate Website
Welcome to UCB in the United States

Newsroom

Find U.S. news and updates from UCB, a global biopharmaceutical company focused on creating value for people living with severe diseases, such as epilepsy, Parkinson’s disease, psoriasis, osteoporosis, myasthenia gravis,  rheumatoid arthritis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and more. 

Spotlight Story

No results

 

 

UCB U.S. News

Powering the dreams of people impacted by myasthenia gravis (MG)

Read More

UCB announces U.S. launch of UCB Myasthenia Gravis Scholarship™ for people impacted by myasthenia…

Read More

UCB Receives U.S. FDA Approval for 320 mg Single-Injection Device Presentations of BIMZELX® (…

Read More

Twitter Feed

For More Information